Travere Therapeutics Expands Kidney Pipeline with Civorebrutinib, $112.5M Upfront, $1.03B Milestones
TVTX has more than doubled off its 52-week low of $13.88.
Summary
Travere Therapeutics has secured exclusive rights to civorebrutinib from Everest Medicines for development and commercialization outside of certain Asian territories. The agreement includes an upfront payment of $112.5 million and potential milestone payments totaling up to $1.03 billion across five indications. This follows an 8-K filed earlier today and significantly expands Travere's kidney disease pipeline with a new BTK inhibitor, diversifying its drug portfolio. The substantial upfront and potential milestone payments highlight the strategic importance and perceived value of this new asset.
At the time of this announcement, TVTX was trading at $46.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $13.88 to $48.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.